All Stories

  1. The regulatory role of APE1 in epithelial-to-mesenchymal transition and in determining EGFR-TKI responsiveness in non-small-cell lung cancer

    Article • Cancer Medicine, August 2018, Wiley

    Professor Gianluca Tell, Yu Peng

  2. Small-molecule BH3 mimetic and pan-Bcl-2 inhibitor AT-101 enhances the antitumor efficacy of cisplatin through inhibition of APE1 repair and redox activity in non-small-cell lung cancer

    Article • Drug Design Development and Therapy, June 2015, Dove Medical Press

    Professor Tao Ren, Yu Peng

  3. Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer

    Article • Drug Design Development and Therapy, February 2015, Taylor & Francis

    Professor Tao Ren, Yu Peng

  4. Sequential treatment with AT-101 enhances cisplatin chemosensitivity in human non-small cell lung cancer cells through inhibition of apurinic/apyrimidinic endonuclease 1-activated IL-6/STAT3 signaling pathway

    Article • Drug Design Development and Therapy, December 2014, Taylor & Francis

    Professor Tao Ren, Yu Peng

  5. Association of DNA base excision repair genes (OGG1 , APE1 and XRCC1 ) polymorphisms with outcome to platinum-based chemotherapy in advanced nonsmall-cell lung cancer patients

    Article • International Journal of Cancer, April 2014, Wiley

    Professor Tao Ren, Yu Peng